Medtronic : SMART Trial three-year data demonstrate superior benefits with Evolut TAVR™ system

About this update from Medtronic Plc.

Medtronic, a global leader in healthcare technology, today released the three-year results of the SMall Annuli Randomized To Evolut or SAPIEN (SMART) Trial, the largest international head-to-head comparative trial of transcatheter aortic valve replacement (TAVR). In patients with aortic stenosis (AS) and a small aortic annulus, results showed all individual and composite hemodynamic measures continue to be superior at three years for Evolut™ TAVR compared to SAPIEN™. The science was presented [...] This is an abstract of the document. To keep reading, click here and get access to the original version.

View stock analysis, news, and events for Medtronic Plc.